KC7F2
Based on 24 publication(s) in Google Scholar
KC7F2 is a potent hypoxia inducible factor-1 (HIF-1) pathway inhibitor with an IC50 of 20 μM in LN229-HRE-AP cells, and with potential as a cancer therapy agent.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.36%
- CAS No.: 927822-86-4
- Formule: C16H16Cl4N2O4S4
- Masse moléculaire:570.38
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Epigenetics Compound Library
HY-L005
-
Immunology/Inflammation Compound Library
HY-L007
-
Metabolism/Protease Compound Library
HY-L012
-
Anti-Cancer Compound Library
HY-L025
-
Reprogramming Compound Library
HY-L039
-
Oxygen Sensing Compound Library
HY-L045
-
Glutamine Metabolism Compound Library
HY-L064
-
Anti-Breast Cancer Compound Library
HY-L074
-
Anti-Cancer Metabolism Compound Library
HY-L083
-
Angiogenesis-Related Compound Library
HY-L088
-
Transcription Factor-Targeted Library
HY-L090
-
Targeted Diversity Library
HY-L099
-
Cancer Stem Cells Compound Library
HY-L135
-
Metabolic Enzyme Compound Library
HY-L146
-
Anti-Ovarian Cancer Compound Library
HY-L173
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Anti-Fibrosis Compound Library
HY-L185
-
Lactic Acid Metabolic Compound Library
HY-L204
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) KC7F2
More- J Adv Res. 2026 May 3:S2090-1232(26)00380-2. [Abstract]
- Redox Biol. 2026 Jan 5:89:104008. [Abstract]
- Acta Pharm Sin B. 2024 May;14(5):2097-2118. [Abstract]
- Cell Death Dis. 2023 Nov 7;14(11):722. [Abstract]
- J Neuroinflammation. 2019 Nov 28;16(1):240. [Abstract]
- Acta Pharmacol Sin. 2023 May;44(5):940-953. [Abstract]
- Mol Ther Oncolytics. 2022 Aug 5:26:372-386. [Abstract]
- Mol Med. 2024 Jun 12;30(1):83. [Abstract]
- Free Radic Biol Med. 2022 Oct:191:119-127. [Abstract]
- Anal Chem. 2025 Jun 3;97(21):11099-11109. [Abstract]
- Pharmaceutics. 2024 Aug 27;16(9):1130. [Abstract]
- J Ethnopharmacol. 2023 May 23:308:116289. [Abstract]
- Oncogenesis. 2020 Sep 11;9(9):81. [Abstract]
- J Cell Mol Med. 2021 Jun;25(12):5457-5469. [Abstract]
- FASEB J. 2026 Jun 15;40(11):e71979. [Abstract]
- Front Biosci (Landmark Ed). 2022 Jan 17;27(1):23. [Abstract]
- J Radiat Res Appl Sci. 2026 May 1;19(2):102423.
- Int J Biochem Cell Biol. 2024 Apr:169:106541. [Abstract]
- BMC Anesthesiol. 2019 Jul 9;19(1):127. [Abstract]
- Biochim Biophys Acta Gen Subj. 2023 Dec 27;1868(3):130548. [Abstract]
- Gene. 2025 Mar 26:954:149435. [Abstract]
- SSRN. 2026 Apr 11.
- Research Square Preprint. 2024 Jan 1.
- Research Square Preprint. 2021 Nov.
Customer Validation & Images
-
Others
-
WB
-
WB
-
WB
-
RT-PCR
Activité biologique
IC50: 20 μM (HIF-1, LN229-HRE-AP cells)[1]
KC7F2 (15–25 μM; 0-72 hours) exhibits a clear dose-response cytotoxicity with an IC50 value of approximately 15–25 μM depending on the cell lines, and this effect is more severe under hypoxic conditions[1].
KC7F2 (0-80 μM; 6 hours) specifically reduces the protein levels of HIF-1α in a dose-dependent manner under hypoxic conditions; strongly decrease in HIF-1α levels at concentrations above 20 μM[1].
KC7F2 does not affect the rate of HIF-1α protein degradation[1].
KC7F2 inhibits HIF-1α protein synthesis but not its mRNA transcription[1].
KC7F2 represses the phosphorylation of eukaryotic initiation factor 4E binding protein 1 (4EBP1)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MCF7 cells, LNZ308 cells, A549 cells, U251MG cells, LN229 cells
-
Concentration:15–25 μM
-
Incubation Time:0-72 hours
-
Result:With cytotoxicity more pronounced in tumor cell lines as compared to normal cells.
-
Cell Line:LN229 cells
-
Concentration:6 hours
-
Incubation Time:0 μM, 5 μM,7.5 μM,10 μM,15 μM,20 μM,30 μM,40 μM,60 μM,80 μM
-
Result:Decreases HIF-1α protein levels in a dose-dependent manner.
Chemical Information
-
CAS No. 927822-86-4
-
Appearance Solid
-
Masse moléculaire 570.38
-
Formule C16H16Cl4N2O4S4
-
Color White to off-white
-
SMILES
O=S(C1=CC(Cl)=CC=C1Cl)(NCCSSCCNS(C2=CC(Cl)=CC=C2Cl)(=O)=O)=O
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (24)
-
Journal Impact Factor
-
Most Recent
-
J Adv Res
Low temperatures enhance PM2.5-mediated mitochondrial dysfunction in the pig lung-intestinal axis, causing damage to the gut. [Abstract]2026 May 3:S2090-1232(26)00380-2. PMID: 42086185 -
Redox Biol
Porcine epidemic diarrhea virus promotes viral replication via ROS/HIF-1α-mediated glycolysis. [Abstract]2026 Jan 5:89:104008. PMID: 41512444 -
Acta Pharm Sin B
2024 May;14(5):2097-2118. PMID: 38799640
KC7F2 purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2024 May;14(5):2097-2118. [Abstract]
Dual-luciferase reporter assay to detect the activity of Chat in NSCs stably transfected with the reporter construct pGL4.27 or pGL4.27-Chat. A HIF-1α inhibitor of KC7F2 was applied to NSCs from TG mice transfected with pGL4.27-Chat.
-
Cell Death Dis
Pyruvate dehydrogenase kinase 1 protects against neuronal injury and memory loss in mouse models of diabetes. [Abstract]2023 Nov 7;14(11):722. PMID: 37935660
KC7F2 purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2023 Nov 7;14(11):722. [Abstract]
KC7F2 (40 μM). Western blot analysis of PDK1, p-S293-PDH, p-S300-PDH and PDH-E1 in each group.
-
J Neuroinflammation
Monocarboxylate transporter 1 promotes classical microglial activation and pro-inflammatory effect via 6-phosphofructo-2-kinase/fructose-2, 6-biphosphatase 3. [Abstract]2019 Nov 28;16(1):240. PMID: 31779643
KC7F2 purchased from MedChemExpress. Usage Cited in: J Neuroinflammation. 2019 Nov 28;16(1):240. [Abstract]
The overexpression efficiency of Lenti-MCT1 and quantification of the mRNA level of PFKFB3 in each group (n = 4 per group). KC7F2, an inhibitor of Hif-1α, 30 mM.
-
Acta Pharmacol Sin
Inhibiting von Hippel‒Lindau protein-mediated Dishevelled ubiquitination protects against experimental parkinsonism. [Abstract]2023 May;44(5):940-953. PMID: 36357669
KC7F2 purchased from MedChemExpress. Usage Cited in: Acta Pharmacol Sin. 2023 May;44(5):940-953. [Abstract]
Representative immunoblots of HIF-1α, TH and β-actin in different groups of cells preincubated with/without KC7F2 (5 μM) for 1 h.
-
Mol Ther Oncolytics
Berberine inhibits carcinogenesis through antagonizing the ATX-LPA-LPAR2-p38-leptin axis in a mouse hepatoma model. [Abstract]2022 Aug 5:26:372-386. PMID: 36090480 -
Mol Med
Aerobic exercise-induced HIF-1α upregulation in heart failure: exploring potential impacts on MCT1 and MPC1 regulation. [Abstract]2024 Jun 12;30(1):83. PMID: 38867145 -
Free Radic Biol Med
LRRK2 deficiency protects the heart against myocardial infarction injury in mice via the P53/HMGB1 pathway. [Abstract]2022 Oct:191:119-127. PMID: 36055602 -
Anal Chem
Exposome-Scale Investigation of Cl-/Br-Containing Chemicals Using High-Resolution Mass Spectrometry, Multistage Machine Learning, and Cloud Computing. [Abstract]2025 Jun 3;97(21):11099-11109. PMID: 40401576 -
Pharmaceutics
Carrier-Free Hybrid Nanoparticles for Enhanced Photodynamic Therapy in Oral Carcinoma via Reversal of Hypoxia and Oxidative Resistance. [Abstract]2024 Aug 27;16(9):1130. PMID: 39339168 -
J Ethnopharmacol
DiDang decoction improves mitochondrial function and lipid metabolism via the HIF-1 signaling pathway to treat atherosclerosis and hyperlipidemia. [Abstract]2023 May 23:308:116289. PMID: 36822344
KC7F2 purchased from MedChemExpress. Usage Cited in: J Ethnopharmacol. 2023 May 23:308:116289. [Abstract]
KC7F2 upregulates the expression of Bcl2 and downregulates the expression of Bax in L02 cells.
-
Oncogenesis
Hypoxia induces an endometrial cancer stem-like cell phenotype via HIF-dependent demethylation of SOX2 mRNA. [Abstract]2020 Sep 11;9(9):81. PMID: 32913192 -
J Cell Mol Med
HIF-1α is necessary for activation and tumour-promotion effect of cancer-associated fibroblasts in lung cancer. [Abstract]2021 Jun;25(12):5457-5469. PMID: 33943003 -
FASEB J
Roxadustat Ameliorates Thoracic Aortic Dissection by Activating HIF-1α-Mediated Mitophagy to Inhibit Ferroptosis. [Abstract]2026 Jun 15;40(11):e71979. PMID: 42201682 -
Front Biosci (Landmark Ed)
Increased expression of PD-L1 in endometrial cancer stem-like cells is regulated by hypoxia. [Abstract]2022 Jan 17;27(1):23. PMID: 35090328 -
-
Int J Biochem Cell Biol
Tumor necrosis factor α-induced protein 8-like-2 controls microglia phenotype via metabolic reprogramming in BV2 microglial cells and responses to neuropathic pain. [Abstract]2024 Apr:169:106541. PMID: 38309648 -
BMC Anesthesiol
Propofol attenuated TNF-α-modulated occludin expression by inhibiting Hif-1α/ VEGF/ VEGFR-2/ ERK signaling pathway in hCMEC/D3 cells. [Abstract]2019 Jul 9;19(1):127. PMID: 31288745
KC7F2 purchased from MedChemExpress. Usage Cited in: BMC Anesthesiol. 2019 Jul 9;19(1):127. [Abstract]
The hCMEC/D3 cells are treated with TNF-α, propofol, and Hif-1α inhibitor (KC7F2, 10 μM). Left side shows the image of a representative Western blot for Hif-1α, VEGF, p-VEGFR-2, p-ERK, ERK and occludin. Right side is the plot of normalized ratios of optical densities. β-actin is served as internal loading control.
-
Biochim Biophys Acta Gen Subj
Roxadustat ameliorates experimental colitis in mice by regulating macrophage polarization through increasing HIF level. [Abstract]2023 Dec 27;1868(3):130548. PMID: 38158022 -
Gene
2025 Mar 26:954:149435. PMID: 40154584 -
-
-
Solvant et solubilité
DMSO : ≥ 32 mg/mL (56.10 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.5 mg/mL (4.38 mM); Clear solution; Need ultrasonic
This protocol yields a clear solution of 2.5 mg/mL.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (273 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instruction de manipulation (2659 KB)
Références
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.7532 mL | 8.7661 mL | 17.5322 mL | 43.8304 mL |
| 5 mM | 0.3506 mL | 1.7532 mL | 3.5064 mL | 8.7661 mL | |
| 10 mM | 0.1753 mL | 0.8766 mL | 1.7532 mL | 4.3830 mL | |
| 15 mM | 0.1169 mL | 0.5844 mL | 1.1688 mL | 2.9220 mL | |
| 20 mM | 0.0877 mL | 0.4383 mL | 0.8766 mL | 2.1915 mL | |
| 25 mM | 0.0701 mL | 0.3506 mL | 0.7013 mL | 1.7532 mL | |
| 30 mM | 0.0584 mL | 0.2922 mL | 0.5844 mL | 1.4610 mL | |
| 40 mM | 0.0438 mL | 0.2192 mL | 0.4383 mL | 1.0958 mL | |
| 50 mM | 0.0351 mL | 0.1753 mL | 0.3506 mL | 0.8766 mL |
KC7F2 Related Classifications
HY-18777 Related Classifications
Powered by Bioz